CompletedPhase 2Phase 3ACTRN12608000291381

Pilot Trial of Transversus Abdominis Plane Ropivacaine Infusions following Abdominal Surgery

The Analgesic Efficacy of Ultrasound Guided Transversus Abdominis Plane Ropivacaine Continuous Blockade in Patients Undergoing Abdominal Surgery - Pilot Trial


Sponsor

Western Health

Enrollment

20 participants

Start Date

Aug 1, 2008

Study Type

Interventional

Conditions

Summary

This is a pilot trial looking at the safety and feasability of running a local anaesthetic infusion to improve the post-operative pain relief of patients who have had abdominal surgery. The local anaesthetic, called ropivacaine, will be run via a transversus abdominis plane catheter. This will be placed in both sides of the abdomen between two muscle layers. The study will look at the effect of the infusion on how much morphine the patient requires after their surgery. The study will also look at the levels of ropivacaine in the blood during the infusion, which will run for three days.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This pilot trial tests whether delivering a local anesthetic through catheters placed in the abdominal wall can reduce pain after abdominal surgery. It is for adults aged 18 or older having planned abdominal surgery with a midline incision who do not have chronic pain or opioid tolerance.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Transversus abdominis plane infusion using ropivacaine 0.2%, 0.1mL/kg/hr bilaterally. Infusion rate rounded down to the nearest integer. Maximum of 7mL/h bilaterally. 72 hr duration of infusion.

Transversus abdominis plane infusion using ropivacaine 0.2%, 0.1mL/kg/hr bilaterally. Infusion rate rounded down to the nearest integer. Maximum of 7mL/h bilaterally. 72 hr duration of infusion.


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000291381